FA
REGN icon

Forefront Analytics’s Regeneron Pharmaceuticals REGN Stock Holding History

Forefront Analytics’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$355K Buy
460
+33
+8% +$25.3K 0.32% 26
2025
Q4 		$329K Buy
427
+15
+4% +$10.2K 0.29% 29
2025
Q3 		$232K Sell
412
-78
-16% -$44.1K 0.22% 35
2025
Q2 		$257K Buy
+490
New +$273K 0.29% 32
2025
Q1 		– Sell
-368
Closed -$262K – 59
2024
Q4 		$262K Buy
368
+71
+24% +$59.6K 0.12% 49
2024
Q3 		$312K Sell
297
-31
-9% -$34.5K 0.15% 53
2024
Q2 		$345K Sell
328
-16
-5% -$15.5K 0.17% 52
2024
Q1 		$331K Buy
344
+25
+8% +$23.8K 0.16% 52
2023
Q4 		$280K Buy
319
+26
+9% +$21.4K 0.14% 53
2023
Q3 		$241K Sell
293
-48
-14% -$37.7K 0.14% 51
2023
Q2 		$245K Sell
341
-16
-4% -$12.3K 0.14% 51
2023
Q1 		$293K Buy
357
+50
+16% +$37.7K 0.15% 55
2022
Q4 		$221K Sell
307
-8
-3% -$5.9K 0.12% 60
2022
Q3 		$216K Buy
+315
New +$198K 0.12% 48
2022
Q2 		– Sell
-515
Closed -$353K – 71
2022
Q1 		$353K Buy
515
+123
+31% +$77.8K 0.13% 42
2021
Q4 		$249K Buy
392
+10
+3% +$6.15K 0.08% 50
2021
Q3 		$233K Sell
382
-40
-9% -$24.8K 0.08% 52
2021
Q2 		$235K Sell
422
-83
-16% -$42K 0.09% 53
2021
Q1 		$238K Buy
+505
New +$246K 0.1% 49

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Forefront Analytics's REGN Position: Q1 2026 in Review

Forefront Analytics increased its Regeneron Pharmaceuticals (REGN) stake by 7.7% in Q1 2026, buying an estimated $25.3K and bringing the position to 460 shares worth $355K. The position accounts for 0.32% of the portfolio, ranked #26.

Forefront Analytics first reported a position in REGN in Q1 2021 and has held it in 19 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Forefront Analytics held 460 shares of Regeneron Pharmaceuticals worth $355K as of Q1 2026.
  • Forefront Analytics bought 33 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $25.3K.
  • Regeneron Pharmaceuticals made up 0.32% of Forefront Analytics's portfolio in Q1 2026, its #26 holding.
  • Forefront Analytics first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Forefront Analytics's 13F filing for Q1 2026, filed 13 May 2026.